EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 / No 5 (Mai 2005) Med Sci (Paris), 21 5 (2005) 507-511 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Number 5, Mai 2005
Page(s) 507 - 511
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005215507
Published online 15 May 2005
  1. Issemann, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347 : 645–50. [Google Scholar]
  2. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 2001; 79 : 30–47. [Google Scholar]
  3. Komar CM, Braissant O, Wahli W, Curry TE Jr. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 2001; 142 : 4831–8. [Google Scholar]
  4. Froment P, Fabre S, Dupont J, et al. Expression and functional role of peroxisome proliferator-activated receptor-gamma in ovarian folliculogenesis in the sheep. Biol Reprod 2003; 69 : 1665–74. [Google Scholar]
  5. Mouihate A, Boisse L, Pittman QJ. A novel antipyretic action of 15-deoxy-Delta12,14-prostaglandin J2 in the rat brain. J Neurosci 2004; 24 : 1312–8. [Google Scholar]
  6. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands : novel therapy for pituitary adenomas. J Clin Invest 2003; 111 : 1381–8. [Google Scholar]
  7. Gasic S, Bodenburg Y, Nagamani M, et al. Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 1998; 139 : 4962–6. [Google Scholar]
  8. Lohrke B, Viergutz T, Shahi SK, et al. Detection and functional characterisation of the transcription factor peroxisome proliferator-activated receptor gamma in lutein cells. J Endocrinol 1998; 159 : 429–39. [Google Scholar]
  9. Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 2002; 66 : 190–8. [Google Scholar]
  10. Mu YM, Yanase T, Nishi Y, et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000; 271 : 710–3. [Google Scholar]
  11. Viergutz T, Loehrke B, Poehland R, et al. Relationship between different stages of the corpus luteum and the expression of the peroxisome proliferator-activated receptor gamma protein in bovine large lutein cells. J Reprod Fertil 2000; 118 : 153–61. [Google Scholar]
  12. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002; 277 : 17830–5. [Google Scholar]
  13. Dunaif A. Insulin resistance and the polycystic ovary syndrome : mechanism and implications for pathogenesis. Endocrinol Rev 1997; 18 : 774–800. [Google Scholar]
  14. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81 : 3299–306. [Google Scholar]
  15. Iuorno MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28 : 153–64. [Google Scholar]
  16. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 2004; 4 : 69–75. [Google Scholar]
  17. La Marca A, Egbe TO, Morgante G, et al. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000; 15 : 21–3. [Google Scholar]
  18. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340 : 1314–20. [Google Scholar]
  19. Duran-Sandoval D, Thomas AC, Bailleul B, et al. Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development. Med Sci (Paris) 2003; 19 : 819–25. [Google Scholar]
  20. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes : is increased fatness commensurate with long-term efficacy ? Int J Obes Relat Metab Disord 2003; 27 : 147–61. [Google Scholar]
  21. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996; 20 : 291–302. [Google Scholar]
  22. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89 : 3835–40. [Google Scholar]
  23. Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S. The metabolic syndrome : peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003; 88 : 2412–21. [Google Scholar]
  24. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26 : 76–80. [Google Scholar]
  25. Hara M, Alcoser SY, Qaadir A, et al. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002; 87 : 772–5. [Google Scholar]
  26. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4 : 585–95. [Google Scholar]
  27. Mohan M, Ryder S, Claypool PL, et al. Analysis of gene expression in the bovine blastocyst produced in vitro using suppression-subtractive hybridization. Biol Reprod 2002; 67 : 447–53. [Google Scholar]
  28. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4 : 597–609. [Google Scholar]
  29. Wendling O, Chambon P, Mark M. Retinoid X receptors are essential for early mouse development and placentogenesis. Proc Natl Acad Sci USA 1999; 96 : 547–51. [Google Scholar]
  30. Li Q, Cheon YP, Kannan A, et al. A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice. J Biol Chem 2004; 279 : 11570–81. [Google Scholar]
  31. Asami-Miyagishi R, Iseki S, Usui M, et al. Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun 2004; 315 : 497–501. [Google Scholar]
  32. Tarrade A, Schoonjans K, Guibourdenche J, et al. PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 2001; 142 : 4504–14. [Google Scholar]
  33. Nogueiras R, Barreiro ML, Caminos JE, et al. Novel expression of resistin in rat testis : functional role and regulation by nutritional status and hormonal factors. J Cell Sci 2004; 117 : 3247–57. [Google Scholar]
  34. Pritts EA, Zhao D, Ricke E, et al. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002; 87 : 1841–4. [Google Scholar]
  35. Wanichkul T, Han S, Huang RP, Sidell N. Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 2003; 79 (suppl 1) : 763–9. [Google Scholar]
  36. Dufour JM, Vo MN, Bhattacharya N, et al. Peroxisome proliferators disrupt retinoic acid receptor alpha signaling in the testis. Biol Reprod 2003; 68 : 1215–24. [Google Scholar]
  37. Kobayashi T, Niimi S, Kawanishi T, et al. Changes in peroxisome proliferator-activated receptor gamma-regulated gene expression and inhibin/activin-follistatin system gene expression in rat testis after an administration of di-n-butyl phthalate. Toxicol Lett 2003; 138 : 215–25. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.